Compared With ASCT, KCd Shows Potential Utility for Newly Diagnosed, Transplant-Eligible MM
June 8th 2021Compared to upfront autologous stem cell transplantation for newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone produced noninferior results.
Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer
June 8th 2021Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, according to data from the 2021 ASCO Annual Meeting.
Numerically Improved pCR Not Significant With SD-101 Plus Pembrolizumab in HER2– Breast Cancer
June 7th 2021Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.
HRQOL Analysis From CLEAR Trial Further Support Pembrolizumab/Lenvatinib Combo for Frontline RCC
June 7th 2021Across 3 health-related quality of life scales, the combination of pembrolizumab plus lenvatinib had similar or better outcomes than sunitinib for patients with metastatic renal cell carcinoma receiving treatment in the frontline.
Adding Nivolumab to Chemotherapy Improves Outcomes in Resectable NSCLC
June 7th 2021The addition of neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improved pathological complete response rates and showed a greater depth of pathological response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.